Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/30157
Full metadata record
DC FieldValueLanguage
dc.contributor.authorALONSO ABAD, Ariel-
dc.contributor.authorVAN DER ELST, Wim-
dc.contributor.authorMOLENBERGHS, Geert-
dc.contributor.authorFlorez, Alvaro J.-
dc.date.accessioned2019-12-16T13:36:45Z-
dc.date.available2019-12-16T13:36:45Z-
dc.date.issued2019-
dc.identifier.citationJOURNAL OF BIOPHARMACEUTICAL STATISTICS, 29(3), p. 529-540-
dc.identifier.urihttp://hdl.handle.net/1942/30157-
dc.description.abstractAt the beginning of the 21st century, a new paradigm was introduced for the evaluation of surrogate endpoints based on meta-analysis. In this paradigm, the putative surrogate is assessed at two different levels, the so-called, trial and individual level. Trial level surrogacy is defined as the association between the expected causal treatment effects across different trials populations, whereas the individual level is defined as the association between the surrogate and true endpoints, after adjusting by trial and treatment. It has been argued that the individual level surrogacy does not have a causal interpretation and, consequently, it is a poor metric of surrogacy. In the present work, an alternative definition of individual level surrogacy is introduced based on individual causal treatment effects. In addition, using the maximum entropy principle, a direct link between the individual level surrogacy, as defined in the meta-analytic approach, and the newly proposed definition is established. This new perspective sets the individual level surrogacy in a more coherent framework with respect to the trial level and bridges the two main schools of thought in this domain, namely, the causal inference and meta-analytic schools.-
dc.language.isoen-
dc.publisherTAYLOR & FRANCIS INC-
dc.subject.otherCausal inference-
dc.subject.othermeta-analytic approach-
dc.subject.othermaximum entropy-
dc.subject.othersurrogate endpoints-
dc.titleA reflection on the causal interpretation of individual-level surrogacy-
dc.typeJournal Contribution-
dc.identifier.epage540-
dc.identifier.issue3-
dc.identifier.spage529-
dc.identifier.volume29-
local.format.pages12-
local.bibliographicCitation.jcatA1-
dc.description.notes[Alonso, Ariel; Florez, Alvaro J.] Katholieke Univ Leuven, I BioStat, Kapucijnenvoer 35, B-3000 Leuven, Belgium. [Van der Elst, Wim] Janssen Pharmaceut Co Johnson & Johnson, Quantitat Sci, Beerse, Belgium. [Molenberghs, Geert] Univ Hasselt, I BioStat, Diepenbeek, Belgium.-
local.publisher.placePHILADELPHIA-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1080/10543406.2019.1579221-
dc.identifier.isi000469139500009-
item.accessRightsClosed Access-
item.validationecoom 2020-
item.fulltextNo Fulltext-
item.contributorALONSO ABAD, Ariel-
item.contributorVAN DER ELST, Wim-
item.contributorMOLENBERGHS, Geert-
item.contributorFlorez, Alvaro J.-
item.fullcitationALONSO ABAD, Ariel; VAN DER ELST, Wim; MOLENBERGHS, Geert & Florez, Alvaro J. (2019) A reflection on the causal interpretation of individual-level surrogacy. In: JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 29(3), p. 529-540.-
crisitem.journal.issn1054-3406-
crisitem.journal.eissn1520-5711-
Appears in Collections:Research publications
Show simple item record

WEB OF SCIENCETM
Citations

2
checked on Apr 24, 2024

Page view(s)

40
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.